Drugs / AchromoPhage
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07275905 | Aug 2026 → Jan 2028 expected | bacterial infectious disease, cystic fibrosis | Ghady Haidar | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AchromoPhage | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07275905 ↗ |
| Action | Deplete | “AchromoPhage is a mixture of four naturally occurring viruses, called phages, that are designed to target and kill Achromobacter.” NCT07275905 ↗ |
| Modality | Other / unclassified | “AchromoPhage is a naturally derived bacteriophage cocktail composed of four genetically distinct, obligately lytic phages (phiACH01, phiACH04, phiACH06, and phiACH07) with...” NCT07275905 ↗ |
| Route | Inhaled | “via the inhaled route” NCT07275905 ↗ |